Loading company…
MiRdetect develops molecular blood tests for early cancer detection and diagnosis, based in Bremen, Germany.
Founded in 2016 and headquartered in Bremen, Germany, MiRdetect GmbH develops and distributes molecular biological tests for early cancer detection and diagnosis, using a simple blood sample. Its clients include healthcare providers, hospitals and laboratories, particularly in Europe. Initial funding came from BAB Beteiligungs und Managementgesellschaft Bremen mbH and High-Tech Gründerfonds, among others, and the most recent deal was on May 2, 2019.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in